JPRN-UMIN000001963未知2 期
Phase II clinical trial of the third-line Cetuximab and irinotecan or Cetuximab therapy for patients with KRAS wild type unresectable/recurrent colorectal cancer - CEREB trial :CEtuximab,REsearch on Biomarker
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)active other malignancies within 5 years 2) history of the severe drug hypersensitivity 3)clinically significant infectious disease(body temperature less than 38.0 degrees) 4)severe complications(ileus, bowel obstruction, interstitial lung disease, pulmonary fibrosis, uncontrolled diabetes mellitus, heart failure, renal failure, hepatic failure and so on) 5) Patients who have abnormal findings on ECG and need any treatment (within 4 weeks before the registration.) 6) Moderate/severe pleural effusion or ascites 7) Symptomatic brain metastasis 8)Patient need transfusion because GI bleeding 9) Uncontrolled watery diarrhea. Watery colostomy output without trouble with patient's daily living is allowed. 10) Pregnant or lactating women, women who are capable of pregnancy or intend to get pregnant, men who don't intend to have protected intercourse. 11) Any other cases who are regarded as inadequate for study enrollment by the investigator.
研究者
相似试验
进行中（未招募）
不适用
A study of the combination of cetuximab and methotrexate in recurrent or metastatic cancer of the head and neck.Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)EUCTR2013-002886-20-NLMC St Radboud
已完成
2 期
A phase Ib-II study of the combination of cetuximab and methotrexate in recurrent or metastatic squamous cell carcinoma of the head and neck. A study of the Dutch Head and Neck Society. DHNS 2013-01 / MOHN01cancer of the head and neckSquamous cell carcinoma of the head and neck10027655NL-OMON40553niversitair Medisch Centrum Sint Radboud120
尚未招募
2 期
Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell CarcinomaHend and Neck Squamous Cell Carcinoma Locally Advanced OperableNCT06107114Xuekui Liu52
进行中（未招募）
不适用
A phase II trial and scheduling finding of cetuximab in combination with rapidly alternating chemo-radiation in unresectable,locally advanced, squamous cell carcinoma of the head and neck (HNC)nresectable locally advanced squamous cell carcinoma of the head and neckMedDRA version: 6.1Level: PTClassification code 10007284EUCTR2004-000411-25-ITG.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
进行中（未招募）
1 期
PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA EMMA-1 (ERBITUX FOR MULTIPLE MYELOMA) - EMMA-1Relapsed or refractory multiple myelomaEUCTR2005-005612-24-DEniversity of Cologne